---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-004197"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:18:52.139891+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sangamo reports updated Phase 1/2 STAAR data for ST-920; eGFR slope +3.061; FDA Accelerated Approval path confirmed

## Summary
- 33 patients treated; gene therapy ST-920 generally well-tolerated; no deaths or discontinuations.
- ERT-naïve/pseudo-naïve patients showed sustained α-Gal A activity up to 42 months; 17/18 ERT patients remain off ERT.
- 23 patients with ≥12 months follow-up: mean annualized eGFR slope +3.061 (95% CI 0.863-5.258), indicating potential kidney improvement.
- FDA agreed to Accelerated Approval using 52-week eGFR slope; BLA submission expected H2 2025.
- Significant QoL (SF-36 General Health +10.6, p=0.0020) and GI symptom improvements; anti-α-Gal A antibodies reduced/eliminated in 9/10 patients.

## SEC filing metadata
- accession: 0001628280-25-004197
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828025004197/0001628280-25-004197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828025004197/sgmo-20250206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-004197
- JSON: https://secwatch.observer/filing/0001628280-25-004197.json
- Plain text: https://secwatch.observer/filing/0001628280-25-004197.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.